Perspective

Split Viewer

Blood Res 2014; 49(1):

Published online March 31, 2014

https://doi.org/10.5045/br.2014.49.1.3

© The Korean Society of Hematology

How do we prepare ourselves for a new paradigm of medicine to advance the treatment of pediatric acute lymphoblastic leukemia?

Kyung Duk Park, M.D. Ph.D.

Pediatric ALL Working Party, Korean Society of Hematology, Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. Davila, ML, Riviere, I, Wang, X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014;6;224ra25.
  2. Pui, CH, Carroll, WL, Meshinchi, S, Arceci, RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol, 2011;29;551-565.
    Pubmed
  3. Inaba, H, Greaves, M, Mullighan, CG. Acute lymphoblastic leukaemia. Lancet, 2013;381;1943-1955.
    Pubmed
  4. Adam de Beaumais, T, Jacqz-Aigrain, E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol, 2012;68;1233-1242.
    Pubmed
  5. Yeoh, AE, Ariffin, H, Chai, EL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol, 2012;30;2384-2392.
    Pubmed
  6. Yeoh, AE, Tan, D, Li, CK, Hori, H, Tse, E, Pui, CH. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol, 2013;14;e508-e523.
    Pubmed
  7. Jang, MJ, Park, HJ, Yoon, SS, et al. Health insurance system for hematologic diseases: what should we do?. Korean J Hematol, 2011;46;6-8.
    Pubmed

Article

Perspective

Blood Res 2014; 49(1): 3-4

Published online March 31, 2014 https://doi.org/10.5045/br.2014.49.1.3

Copyright © The Korean Society of Hematology.

How do we prepare ourselves for a new paradigm of medicine to advance the treatment of pediatric acute lymphoblastic leukemia?

Kyung Duk Park, M.D. Ph.D.

Pediatric ALL Working Party, Korean Society of Hematology, Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Davila, ML, Riviere, I, Wang, X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 2014;6;224ra25.
    2. Pui, CH, Carroll, WL, Meshinchi, S, Arceci, RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol, 2011;29;551-565.
      Pubmed
    3. Inaba, H, Greaves, M, Mullighan, CG. Acute lymphoblastic leukaemia. Lancet, 2013;381;1943-1955.
      Pubmed
    4. Adam de Beaumais, T, Jacqz-Aigrain, E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol, 2012;68;1233-1242.
      Pubmed
    5. Yeoh, AE, Ariffin, H, Chai, EL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol, 2012;30;2384-2392.
      Pubmed
    6. Yeoh, AE, Tan, D, Li, CK, Hori, H, Tse, E, Pui, CH. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol, 2013;14;e508-e523.
      Pubmed
    7. Jang, MJ, Park, HJ, Yoon, SS, et al. Health insurance system for hematologic diseases: what should we do?. Korean J Hematol, 2011;46;6-8.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download